Dongwu Securities atribui a Hui Tai Medical a classificação de "Compra": crescimento sólido dos resultados, divulgação de incentivo de ações que demonstra confiança no crescimento a longo prazo

每经AI快讯，东吴证券3月26日发布研报称，给予惠泰医疗（688617.SH，最新价：236元）"买入"评级。
A Every day AI news flash, Dongwu Securities released a research report on March 26, giving Huatai Medical (688617.SH, latest price: 236 yuan) a “buy” rating.
评级理由主要包括：1）核心产品稳健增长，主要产品线毛利率均同比提升；
The reasons for the rating mainly include: 1) Core products show stable growth, and the gross margins of major product lines have increased year-on-year;
2）发布股权激励，彰显长期增长信心；
2) Issued equity incentives, demonstrating confidence in long-term growth;
3）2025年电生理推广顺利，各产品线市场覆盖率进一步提高。
3) The promotion of electrophysiology in 2025 is progressing smoothly, and the market coverage of each product line is further increased.
风险提示：市场竞争风险，政策风险等。
Risk warning: market competition risks, policy risks, etc.

每经头条（nbdtoutiao）——别再说产能过剩！美伊战争暴露真相，全球新能源缺口巨大，多国瞄准中国先进产业链
Every day headline (nbdtoutiao) - Stop saying that there is overcapacity! The US-Iran war exposes the truth, the global new energy gap is huge, and many countries are targeting China’s advanced industrial chain.

（记者 王晓波）
(Reporter Wang Xiaobo)

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any actions taken based on this are at your own risk.

每日经济新闻
Daily Economic News